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ABSTRACT 
Objective: Food intake normally stimulates release of satiety and insulin-stimulating 
intestinal hormones, such as glucagon-like peptide (GLP)-1. This response is blunted in obese 
insulin resistant subjects, but is rapidly restored following Roux-en-Y gastric bypass (RYGB) 
surgery. We hypothesized this a result of the metabolic changes taking place in the small 
intestinal mucosa following the anatomical rearrangement after RYGB surgery, and aimed at 
identifying such mechanisms. 
Design: Jejunal mucosa biopsies from patients undergoing RYGB surgery were retrieved at 
time of operation, before and after very-low calorie diet, and 6 months postoperatively. 
Samples were analyzed by global protein expression analysis and Western blotting. 
Biological functionality of these findings was explored in mice and primary jejunal cell 
cultures. 
Results: The most prominent change found after RYGB was decreased jejunal expression of 
the rate-limiting ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA 
synthase (mHMGCS), corroborated by decreased ketone body levels. In mice, prolonged 
high-fat feeding induced the expression of mHMGCS and functional ketogenesis in jejunum. 
The effect of ketone bodies on gut peptide secretion was subsequently tested on 
enteroendocrine cells (EECs) in mouse primary jejunal cultures, where a 40% inhibition of 
GLP-1 release was found compared to baseline. 
Conclusion: Intestinal ketogenesis is induced by high-fat diet and inhibited by RYGB 
surgery. In cell culture, ketone bodies inhibited GLP-1 release from EECs. Thus, we suggest 
that this may be a mechanism by which RYGB can remove the inhibitory effect of ketone 
bodies on EECs, thereby restituting the responsiveness of EECs resulting in increased meal-
stimulated levels of GLP-1 after surgery.  
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Summary box 
1. What is already known about this subject? 
Roux-en-Y Gastric Bypass surgery for obesity has rapid, non-weight-dependent 
effects on glucose metabolism that cannot be explained by perioperative starvation 
alone. 
2. What are the new findings? 
 
Intestinal ketogenesis, induced by prolonged high-fat feeding, may be a mechanism 
blunting GLP-1 responsiveness in obese subjects before surgery. After Gastric 
Bypass-surgery, this mechanism may be relieved by the inhibition of intestinal 
ketogenesis, promoting the rapid improvement of the GLP-1 response after surgery. 
3. How might it impact on clinical practice in the foreseeable future? 
It may be possible to pharmaceutically target intestinal ketogenesis and thereby 
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INTRODUCTION 
Roux-en-Y gastric bypass (RYGB) is effective in long-term treatment of morbid obesity and 
type-2 diabetes [1]. Weight loss per se is an important factor behind the improved metabolic 
state, but RYGB also activates early postoperative weight-independent mechanisms, for 
example the meal-induced release of gut peptides [2, 3]. Such RYGB associated effects have 
highlighted the effects of the anatomical reconfiguration of the alimentary tract in whole-body 
metabolism. Therefore, we used RYGB as a model to try to find novel intestinal-associated 
mechanisms in the proximal small intestine to improved glucose metabolism. 
 
Following RYGB the former midgut jejunum becomes the alimentary limb anastomosed to a 
30ml gastric pouch at the esophagogastric junction. Food has to pass 1.5 m in the alimentary 
limb to the jejuno-jejunostomy before enzymatic digestion starts. Surprisingly small changes 
occur in the morphological appearance of the jejunal mucosa of the alimentary limb [4, 5]. 
However, functional studies suggest that the digestion-deprived alimentary limb fails to 
assimilate luminal glucose [6-8]. Apparently, it undergoes an induction of glucose uptake 
from the blood circulation, potentially with a glycemia lowering effect [8, 9]. It is likely that 
pre-processing of triglycerides by bile and gastric and pancreatic lipase is deficient. 
Therefore, food digestion and nutrient-absorption become localized mainly to the distal 
jejunum and ileum. Increased stimulation of enteroendocrine cells (EECs) by undigested food 
in the distal small intestine has been suggested as the main mechanism causing the augmented 
release of enteroendocrine gut peptides e. g. gastric inhibitory peptide, peptide YY and 
glucagon-like peptide-1 (GLP-1). As additional theory, it has been suggested that preventing 
exposure of proximal gastrointestinal tract to food could inhibit the release of a hitherto 
unknown “anti-incretin” factor that reduces insulin release or decreases insulin sensitivity, 
and its demise could explain the rapid improvement of gut-peptide release and glucose 
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metabolism after RYGB surgery [9, 10]. The present study was initiated in order to search for 
such novel glucose-lowering mechanisms after RYGB. 
 
MATERIALS AND METHODS 
Surgery and patients 
Anthropometric characteristics of the patient pilot study cohorts are shown in Table 1. 
Patients in the proteomics cohort either underwent primary RYGB (4 patients) or a 
conversion from vertical banded gastroplasty to RYGB (3 patients). In the confirmatory 
cohort, 9 patients were included, 8 of whom underwent a primary RYGB and one underwent 
conversion from vertical banded gastroplasty to RYGB. In the diet cohort, 12 patients were 
recruited to also include mucosa sampling before the start of the two-week very-low-calorie 
diet (VLCD) preceding RYGB surgery. Samples were retrieved as previously described [5].  
In brief, during RYGB surgery, a few centimeters of the jejunum 50-60 cm distal to ligament 
of Treitz was retrieved for research purposes when omega-loop, between the gastro-
enterostomy and the jejuno-jejunostomy, was divided to create the final Roux-en-Y 
construction (Supplementary Figure 1A, left panel). The mucosa/submucosa was separated 
from the musculature by sharp dissection. Before surgery in the diet cohort, and six to eight 
months after surgery in all cohorts, patients underwent an endoscopic examination of the 
jejunum/Roux limb to retrieve mucosa samples (Supplementary Figure 1A, right panel). All 
endoscopies were performed for research purposes. Mucosal tissue specimens were snap-
frozen in liquid nitrogen and kept frozen at -70°C. In these pilot studies, the number of 
patients included was arbitrarily based on estimations of feasibility of samples size in the 
global proteomics analysis. The confirmatory samples were retrieved from cohorts where all 
pre-, peri- and postoperative samples were available. This study was approved by the 
Regional Ethics Review Board of Gothenburg, approval numbers 193-02, 647-05 and 007-09,  
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and performed in accordance with the Declaration of Helsinki. All patients signed informed 
consent before inclusion in the study.  
 








Female 4 (57.1%) 7 (77.8%) 8 (66.7%) 
Diabetes  2 (28.6%) 4 (44.4%) 6 (50%) 
Re-gastroplasty 3 (42.9%) 1 (11.1%) 0 (0%) 
 Median Average Median Average Median Average 
Age 46 46.0 49 50.4 56.5 52.8 
BMI peri-op. 41.6 40.7 40.3 40.3 39.1 39.6 
BMI post-op. 30.0 31.3 31.8 31.8 30.3 30.7 
BMI change -8.9 -9.4 -8.8 -8.5 -9.0 -8.9 
%EBMIL 66.4 58.9 59.4 58.2 61.9 61.3 
 
BMI=Body mass index (kg/m2) 
%EBMIL=Percent excess BMI loss 
 
 
Global protein expression analysis of human jejunal mucosa  
The technique has been described earlier [11]. Only proteins being consistently changed in all 
patients and with at least a 50% change from baseline were included for further analysis. 
 
Animal studies 
Four- to five-week-old male and female C57BL/6J mice were purchased from Harlan (Horst, 
Netherlands). Animals were maintained under controlled temperature (23C) and light (lights 
on, 6:30–18:30 hrs), with ad libitum access to water and pelleted food (R34 Lactamin, 
Kimstad, Sweden) with a nutrient content of g%: fat 4%, protein 16.5%, carbohydrate 58.0%; 
total calorific content: 3 kcal/g. For HFD experiments, six- to eight-week-old male mice were 
fed high-fat diet (HFD) or low-fat diet (LFD) for 3 weeks or 3 months. The HFD consisted of 
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pelleted food (Surwit Diabetogenic Rodent Diet, D12309; Research Diets, New Brunswick, 
NJ) and had a nutrient content in g%: fat 35.9%, protein 23%, carbohydrate 35.5%; total 
calorific content: 5.6 kcal/g. The LFD animals continued to receive their usual diet (R34). All 
animal procedures were approved by the animal ethics committee of the University of 
Gothenburg, approval numbers 90-2007 and 246-2009. 
 
In the first set of experiments the mice were sacrificed after 3 weeks of either LFD or HFD 
and different parts of the small intestine; duodenum (proximal 3 cm), jejunum (middle 3 cm) 
and ileum (distal 3 cm), as well as the liver, were sampled. Full thickness samples of 
intestinal wall and one liver lobe were snap-frozen in liquid nitrogen and kept frozen (-70°C) 
for later analysis of protein expression by Western blotting (see below). 
 
In a second set of experiments the mice were fed LFD or HFD for 3 months. On the study 
day, food was removed for 45 min before experimentation in order to synchronize feeding 
status. At the start of the experiment an oral gavage with 250 μl of Intralipid® (Soy oil 200 
mg/mL, purified egg phospholipids, glycerol, sodium hydroxide, water; Fresenius Kabi, 
Sweden) was given, containing either vehicle (20 μl of ethyl acetate), 2.5 mg of the 
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHMGCS) inhibitor hymeglusin 
(Santa Cruz Biotechnology, Santa Cruz, CA; dissolved in vehicle) or 25 mg of β-
hydroxybutyrate (βHB, Sigma-Aldrich, St Louis, MO; dissolved in vehicle). At 15, 30 or 120 
min, venous blood samples were retrieved from the tail and βHB was analysed using a 
GlucoMen LX β-ketone sensor (A. Menarini Diagnostics, Firenze, IT).  
 
In a third set of experiments the mice were kept on LFD or HFD for 3 weeks and fasted for 6 
hrs before start of the experiment. Then an oral gavage with 500 μl of Intralipid® (Fresenius 
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Kabi) was given and after an additional 90 min the mice were anaesthetized using isoflurane. 
A laparotomy was performed and the portal vein was identified and punctured using a thin 
needle and blood was collected. Peripheral blood samples were concomitantly drawn from the 
eye. Blood samples were centrifuged to prepare serum. βHB was analysed in serum using an 
EnzyChrom Ketone Body Assay kit (BioAssay Systems, Hayward, CA).  
 
Biopsy homogenization, Western blotting and HB quantification 
For human confirmatory and diet cohorts, and all murine frozen jejunal mucosa specimens, 
tissue samples were prepared as described earlier [11]. For proteomics cohort, proteins had 
already been isolated for global protein expression analysis. For each detected band, density 
was quantified, and expressed as a percentage of the total densities of all bands of that 
specific size on the same membrane. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used as loading control. For antibodies please see Supplementary Table 1. 
 
For HB quantification, tissue homogenates peri- and post-RYGB from the “diet cohort” 
were analyzed using βHB Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI) and 
results normalized to homogenate protein content. 
 
Histology of human jejunal mucosa 
Jejunal mucosal specimens retrieved from patients peri- and post-RYGB (n=5, random 
selection from confirmatory cohort) were processed according to standard procedures for 
histology specimen preparation. Briefly, biopsies were fixed in phosphate-buffered 4% 
formaldehyde, dehydrated and embedded in paraffin. Embedded biopsies were cut in 5 m 
sections. For immunofluorescence, sections were rehydrated, antigens were retrieved and 
sections were blocked in 5% normal goat serum (31872, ThermoFisher Scientific, Rockford, 
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IL) before incubation with primary antibody overnight at 4C. Slides were then washed and 
incubated with secondary antibody for 2 hrs. at room temperature and counter-stained with 
Hoechst staining (H6024, Sigma-Aldrich). For antibodies please see Supplementary Table 1. 
Sections with blocking buffer instead of primary antibody were included as negative controls. 
For general histology, hematoxylin & eosin staining was performed according to standard 
procedures. 
 
Mouse jejunal primary culture and GLP-1 secretion quantification 
Mouse jejunal primary cultures were prepared from mice on C57BL6 background conforming 
to the UK Home Office project license 70/7824 and local regulations (Animals (Scientific 
Procedures) Act 1986 Amendment Regulations (SI 2012/3039)  as previously described [12]. 
In brief, the intermediate 10-15 cm region of the small intestine was isolated, digested and 
crypts were isolated. Crypts were then seeded on Matrigel-coated 24-well plates in high 
glucose DMEM supplemented with 10% FBS, 2 mM L-Glutamine and 100 U/mL penicillin 
and 0.1 mg/mL streptomycin and 10 μM Y-27632. The day after plating, cells were washed 
with saline secretion buffer (138 mM NaCl, 4.5 mM KCl, 4.2 mM NaHCO3, 1.2 mM 
NaH2PO4, 2.6 mM CaCl2, 1.2 mM MgCl2, 10 mM HEPES and 0.1% BSA, pH 7.4) with 1 
mM glucose for 30 min. A first hour incubation was performed in secretion buffer with 1 mM 
glucose, supernatant collected and replaced for a second hour with secretion buffer with 
different additives: 10 mM glucose + 0.1 mM 3-isobutyl-1-methylxanthine (IBMX), 10 mM 
glucose + 0.1mM IBMX + 10 mM HB, 10 mM glucose + 0.1 mM IBMX + 0.1 M 
somatostatin. Supernatants were centrifuged for 5 min 1,000 g at 4C to remove any cell 
debris and directly snap-frozen until analysis. Samples were analyzed for total GLP-1 
(Mesoscale Discovery, Rockville, MD) and data were normalized to the first hour secretion 
from the same well. Pertussis toxin (PTX, 500 ng/mL), when used, was added to cells 4-5 hrs. 
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after plating, allowing a 16 hrs. preincubation before the start of the secretion experiment, and 
was included during the secretion experiment. 
 
Patient and public involvement 
The public and patients were not involved in the design, recruitment or conduct of this study.  
 
Statistical analyses  
Student’s t-test was used for analysis of statistical changes in protein levels in the proteomics 
analysis of spot intensities on 2D gel electrophoresis. Two-way ANOVA followed by 
Tukey´s honestly significant difference test was used for analysis of GLP-1 secretion data. 
Non-parametric Wilcoxon signed-rank test was used for paired human data and non-
parametric Mann-Whitney U-test for unpaired mice data. All statistics were performed using 
Prism 7 and 8 (GraphPad, La Jolla, CA). If not otherwise stated, mean and standard error of 
the mean (SEM) are presented in figures.  
 
RESULTS 
RYGB reduced jejunal mHMGCS protein expression  
Intraindividual global protein expression analysis was performed to identify changes in the 
proteome of human mucosal jejunal biopsies retrieved during operation and 6–8 months 
postoperatively. In total, 27 protein spots corresponding to 12 unique proteins passed the 
selection criteria (uni-directionally, regulated by at least 50% from baseline following 
RYGB). The four protein spots with the strongest down-regulation (mean decrease of -3.8-
fold; P<0.001) following RYGB were identified by tandem mass spectrometry as mHMGCS. 
Representative images of the 2D gel electrophoresis are shown in Supplementary Figure 1B. 
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Other proteins identified by this proteomic approach have been published previously [11, 13]. 
A list of all regulated proteins is shown in Supplementary Table 2.  
 
Confirmation of surgery-associated reduction in mucosal mHMGCS and ketone body levels  
Western blotting confirmed the decrease of mHMGCS using the same samples that were used 
for the global proteomics analysis (Figure 1A; one sample from the proteomic analysis had to 
be omitted due to insufficient remaining volume). Blotting-analysis was performed on the 
confirmatory patient cohort showing similar reduction after RYGB (Figure 1B). 
Characteristics for all cohorts are shown in Table 1. Jejunal mucosal levels of the ketone body 
HB were measured in perioperative samples from fasting patients undergone a two-week 
preoperative VLCD, and the same patients 6-8 months after RYGB. The postoperative levels 
were found to be significantly decreased (Figure 1C; peri-RYGB vs. post-RYGB; 
mean±SEM; 70.5±4.7 vs. 39.3±2.2 µM/µg protein, n=11; P<0.001; one sample had to be 
omitted due to technical difficulties). 
  
mHMGCS is localized to the surface epithelial layer in human jejunum  
To study mHMGCS expression morphologically we performed immunostaining of samples 
taken peri- and postoperatively after RYGB (n=5 sample pairs, randomly selected from 
confirmatory cohort). mHMGCS-immunostaining was localised to the epithelium, indicating 
predominant expression in enterocytes. Six months after RYGB, the immunoreactivity to 
mHMGCS was low or absent in all investigated specimens, thus supporting the semi-
quantitative results from the proteomic and blotting-analyses. Figures 1D to 1G show 
representative images of peri- and postoperative staining of mHMGCS in one of the patients. 
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Reduction in mucosal mHMGCS is specific to surgery and is not decreased by preoperative 
very-low-calorie diet 
Blotting-analysis of mucosa samples retrieved from diet cohort before very-low-calorie diet, 
at surgery and after surgery confirmed that reduction of mHMGCS was specific to surgery 
(Figure 2A; pre-VLCD vs. post-VLCD/peri-RYGB vs. post-RYGB; mean±SEM; 1.53±0.18 
vs. 1.32±0.19 vs. 0.31±0.06; n=12). Analysis of lipid metabolism markers CPT1A (Figure 
2B; mean±SEM; 0.91±0.11 vs. 1.49±0.15 vs. 0.83±0.09; n=12), FATP4 (Figure 2C; 
mean±SEM; 0.82±0.11 vs. 1.38±0.16 vs. 1.00±0.10; n=12) and DGAT1 (Figure 2D; 
mean±SEM; 0.67±0.15 vs. 2.24±0.33 vs. 0.51±0.09; n=12) revealed no change comparing 
samples retrieved before diet and after surgery, but an increased expression after VLCD. The 
ketone body utilizing enzyme SCOT was increased after VLCD but no change was seen after 
surgery compared to baseline (Figure 2E; baseline vs. VLCD vs. RYGB; mean±SEM; 
0.93±0.08 vs. 1.49±0.19 vs. 0.77±0.08; n=12). 
  
Mouse intestinal mHMGCS expression is fat sensitive and most pronounced in the jejunum 
To confirm the induction and further investigate the potential functionality of small intestinal 
mucosal mHMGCS protein, animal studies were employed. C57bl/6J mice were fed either 
HFD or LFD over 3 weeks. HFD mice showed significantly higher weight gain compared to 
LFD mice (body weight gain LFD vs. HFD; mean±SEM; 0.94±0.23 vs. 5.84±0.53 g, n=8, 
P<0.001). Western blotting of mHMGCS was performed on specimens from the mucosa of 
the duodenum, the jejunum and the ileum, as well as liver. No difference in mHMGCS 
expression was observed in the duodenum when comparing mice on HFD and LFD (Figure 
3A; LFD vs. HFD; mean±SEM; 1.10±0.23 vs. 1.35±0.18, n=6, P=NS). However, the 
mHMGCS protein expression observed in the jejunum (Figure 3B; LFD vs. HFD; 
mean±SEM; 0.59±0.03 vs. 1.43±0.20, n=5, P<0.01) and ileum (Figure 3C; LFD vs. HFD; 
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mean±SEM; 0.84±0.06 vs. 1.18±0.09, n=6, P<0.05) was significantly higher after HFD than 
LFD. A comparison of mHMGCS expression between the jejunum and the ileum revealed 
substantially higher levels of mHMGCS expression in the jejunum after HFD (Figure 3D; 
jejunum vs. ileum; mean±SEM; 1.39±0.13 vs. 0.70±0.06, n=5/6, P<0.01). mHMGCS 
expression in the liver was somewhat increased (Figure 3E; LFD vs. HFD; mean±SEM; 
0.87±0.04 vs. 1.15±0.07, n=6, P<0.01). 
 
Intralipid gavage in HFD-fed mice results in elevated ketone levels in portal blood  
In order to examine the functionality of mHMGCS expression induced by HFD in mouse 
jejunum, we assessed βHB levels in portal and peripheral venous blood. C57bl/6J mice were 
fed either HFD or LFD during 3 months to robustly induce mHMGCS expression. After oral 
gavage with intralipid to the mice, venous blood was sampled at different times from the tail 
(Figure 3F). HFD mice showed increased βHB levels after 120 min compared to LFD mice 
(Figure 3G; LFD + intralipid vs. HFD + intralipid; mean±SEM; 0.50±0.08 vs. 0.87±0.10 mM, 
n=7, P<0.05). This increase was absent in HFD mice given the mHMGCS inhibitor 
hymeglusin in the oral gavage (Figure 3G; HFD + intralipid vs. HFD + intralipid + 
hymeglusin; mean±SEM; 0.87±0.10 vs. 0.46±0.06 mM, n=7, P<0.01). For mice fed LFD no 
major increase in βHB levels could be seen 120 min after the oral gavage with intralipid, not 
even with addition of exogenous βHB in the oral gavage (Figure 3G; LFD + intralipid + βHB 
vs. HFD + intralipid; mean±SEM; 0.36±0.08 vs. 0.87±0.10 mM, n=8/7, P<0.01). In another 
experiment, we examined βHB levels in portal vs. peripheral venous blood in mice that were 
fed LFD or HFD for 3 weeks. Mice fed HFD had significantly higher baseline levels of βHB 
in the portal vein when normalized to levels in peripheral blood (portal/peripheral blood) in 
contrast to LFD mice (Figure 3H; LFD portal/peripheral vs. HFD portal/peripheral; 
mean±SEM; 0.62±0.04 vs. 1.02±0.10, n=9, P<0.01), showing that the predominant source of 
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βHB shifted between LFD and HFD; with a higher proportion originating from the intestine 
rather than the liver. In the HFD animals, the absolute levels of βHB in portal blood were also 
significantly higher compared to the LFD fed animals (Figure 3I; LFD portal vs. HFD portal; 
mean±SEM; 1.35±0.14 vs. 3.82±0.89 mM, n=9, P<0.05); whereas there was no significant 
difference in the peripheral blood levels (Figure 3I; LFD peripheral vs. HFD peripheral; 
mean±SEM; 2.20±0.22 vs. 3.47±0.65 mM, n=9, P=NS). In the LFD animals, βHB levels were 
significantly lower in portal blood compared to peripheral blood (Figure 3I; LFD peripheral 
vs. LFD portal; mean±SEM; 2.20±0.22 vs. 1.35±0.14 mM, n=9, P<0.01), which was not the 
case in the HFD animals (Figure 3I; HFD peripheral vs. HFD portal; mean±SEM; 3.47±0.65 
vs. 3.82±0.89 mM, n=9, P=NS). These data indicate that the difference between LFD and 
HFD feeding was increased intestinal, rather than decreased hepatic production of βHB. 
 
 
Ketone bodies inhibit glucose-stimulated GLP-1 release from mouse small intestinal EECs  
There are two known fatty acid/ketone receptors expressed on small intestinal EECs. 
FFAR3/GPR41, that is preferentially expressed on small intestinal human and mouse EECs, 
and GPR109a, which is expressed at much lower levels [14, 15]. Therefore, we tested whether 
ketone bodies could have effects on the release of gut peptides from EECs. Primary cultures 
from mouse jejunum were used to measure the effect of HB on basal and glucose- and 
IBMX-stimulated release of the gut peptide GLP-1. The βHB levels were chosen based on an 
approximated molar concentration of βHB in human jejunal mucosa (Figure 1C). The mucosa 
was assumed to constitute a third of the 6 µl cylindrical volume of a 2 mm forceps biopsy 
sample, diluted in buffer to 30 µl in the βHB assay, thus representing a total 15-time dilution. 
Average measured βHB levels in the jejunal samples was 0.8 mM. At a 15-time dilution this 
should reflect a tissue concentration of about 12 mM in vivo. We decided to use βHB at a 
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10mM concentration, and found this to inhibit the glucose/IBMX-stimulated GLP-1 release 
by 43% (Figure 4A; IG + 10 mM HB vs. IG compared to Basal). Somatostatin had an even 
greater inhibitory effect and completely blocked the stimulation induced by glucose/IBMX 
(Figure 4A). As FFAR3 and GPR109a are Gi coupled receptors, we tested whether the 
blocking effect of βHB was mediated via Gi signalling by treating the cell cultures with 
PTX. PTX treatment ablated the inhibitory effect of βHB on GLP-1 release in response to 
glucose/IBMX-stimulation (Figure 4B). PTX also blocked the effect of somatostatin, as 
expected (Figure 4B). Whilst these data do not specifically prove FFAR3 to mediate the 
inhibitory action of HB, they do indicate the involvement of a Gi coupled receptor.  
 
A proposed mechanistic model 
Figure 5 shows a proposed mechanistic model for how high-fat diet dose-dependently may 
inhibit glucose-stimulated release of gut peptides, e. g. GLP-1 from EECs. Chronic fat 
exposure induces increased mHMGCS expression and ketogenesis in jejunal epithelial cells 
(as suggested in Figures 3B, 3F to I and 1C). Ketone bodies (HB) reach the EECs in a 
paracellular fashion and via the microcirculation of villi and act on FFAR3 to inhibit the 
release of GLP-1 (as suggested in Figure 4). RYGB surgery may inhibit this mechanism by 
immediately removing accessibility of FFA as substrate for ketogenesis, and by down-
regulating mHMGCS expression and HB in the jejunum (as shown in Figures 1A to C), 




Very few reports are available on the expression of the rate-limiting ketogenic enzyme 
mHMGCS in human small intestinal mucosa [16]. We show that RYGB surgery per se, and 
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not decreased caloric intake, resulted in a substantial decrease in mHMGCS expression and 
jejunal ketone body levels. The decreased expression and ketone body production after 
surgery could be caused by several different reasons, e. g. substrate unavailability caused by 
decreased lipolysis due to the deviation of bile/pancreatic lipases from the alimentary limb, or 
by increased lipid utilization for anabolic purposes or lipid oxidation for energy demand, 
following the hypertrophy that occurs in the alimentary limb of the jejunum after RYGB [5, 
17, 18].  
 
Ketone bodies are known to be liver-produced during starvation or high-fat low-carbohydrate 
ketogenic diet in order to supply energy for peripheral tissues, including the brain, when 
glucose levels are low. Ketogenesis has an association to short fatty acids like butyrate, which 
both induce mHMGCS expression via PPAR and also act as precursor substrates via -
oxidation [16]. In the small intestine mHMGCS instead has a food intake related expression. 
It has previously been shown to be highly expressed in the early postnatal period in suckling 
rodents, and starvation decreased its expression, in opposition to hepatic ketogenesis [19, 20]. 
After weaning to low-fat diet the expression disappeared from the intestine [20]. It is probably 
the high fat-content of breast milk that induces mHMGCS. Small intestinal expression of 
mHMGCS can also be re-activated by high-fat diet in adult rodents [21, 22]. Thus, intestinal 
ketogenesis could represent a fat-sensory mechanism of the small intestinal mucosa. It seems 
likely that this is a completely different nutrient-mediated signal compared to systemic 
ketogenesis, during which ketones have been suggested to act as systemic signaling 
metabolites that may protect against insulin resistance and type-2 diabetes [23].  
 
In animal experiments, we confirmed that expression of mHMGCS was substantially 
increased in the jejunum after HFD-feeding. This expression lead to increased levels of the 
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ketone body HB in the portal blood of mice. Furthermore, the HB production was 
completely blocked by per-oral pretreatment with the specific mHMGCS-inhibitor 
hymeglusin. The local levels of ketone bodies at the site of production, i.e. the mucosal 
epithelial cells and in the microcirculation of villi may however be substantially higher 
(approximated by our mucosal measurements 10 mM), since portal blood is “diluted” by 
venous return from regions of the intestine other than the jejunum. A potential limitation of 
our study is that it was not possible to obtain postprandial samples for ketone body 
measurement in RYGB-operated patients. It was recently shown that the postprandial fatty 
acid uptake and oxidation was increased (and not decreased) in RYGB-operated rats [18]. 
Whether this reflects a compensatory increase in other parts of the intestine, remains to be 
investigated. 
 
The cessation of inhibitory ketone bodies on EECs could contribute to an increased gut 
peptide responsiveness after RYGB surgery. In cell culture on primary EECs, the ketone body 
βHB inhibited glucose-stimulated GLP-1 release by 40% compared to baseline. This 
inhibition was mediated by a Gi coupled receptor as it was completely reversed by the Gi 
coupled receptor-inhibitor PTX. The Gi coupled ketone body/fatty acid receptor 
FFAR3/GPR41 is expressed in the small intestinal epithelium, where it is highly enriched in 
EECs [14, 15]. It has earlier been demonstrated to be involved in the regulation of energy 
homeostasis, via e.g. PYY and GLP-1 [24]. Our data suggest a new mechanism, as the Gi 
coupled receptor-inhibitor PTX blocked the suppressive effect of both HB and somatostatin 
on GLP-1 release from EECs. However, we could not definitely conclude whether the HB 
induced inhibition of GLP-1 secretion is mediated by FFAR3, or an alternative Gi coupled 
receptor such as GPR109a, in the EECs. GPR109a is however expressed at a much lower 
level in EECs [15].  
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In summary, we suggest a surgical physiological reconstruction of the alimentary limb by 
inducing substrate deficiency for ketogenesis. This could contribute to the explanation of the 
very rapid improvement of incretin hormone secretion observed after RYGB, as we have 
recently shown is evident already two days after surgery [3]. These findings are consistent 
with the proposed “anti-incretin” and “foregut exclusion” hypotheses that could explain the 
effects of RYGB surgery on improved satiety and glucose homeostasis [10]. This may open 
up a new avenue for the development of anti-obesity and anti-diabetic drugs, targeting 
mHMGCS and intestinal mucosal ketone production, in order to increase EEC responsiveness 
and gut peptide release on nutrient stimulation. 
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FIGURE LEGENDS 
Figure 1.   
Western blot analysis of jejunal mHMGCS protein expression peri- and post-RYGB. (A) 
Upper panel shows Western blots of mHMGCS in jejunal samples from the proteomics cohort 
of patients (n=6). Neighboring samples represent pairs of peri- (white bars above) and 
postoperative (grey bars above) samples from the same patient. GAPDH was used as loading 
control and is shown below each corresponding mHMGCS band. Lower panel shows 
densitometric measurement of mHMGCS normalized to GAPDH (arbitrary densitometric 
units; ADU) peri- and post-RYGB. (B) Upper panel shows Western blot of mHMGCS in 
jejunal samples from the confirmatory cohort of RYGB patients peri- and post-RYGB (n=9). 
Group pairs originating from multiple Western blots were merged for presentation of all pairs. 
Lower panel shows densitometric measurement of mHMGCS normalized to GAPDH (ADU; 
arbitrary densitometric units) peri- and post-RYGB. (C) measurement of the ketone 
body HB in human jejunal mucosa samples after a two-week preoperative VLCD and 6-8 
months postoperatively after RYGB surgery in the same patients (n=11). (D) mHMGCS-
immunofluorescence from one patient perioperatively and (E) 6 months postoperatively after 
RYGB. (F) and (G) show corresponding hematoxylin & eosin stainings to panels (D) and (E), 
respectively. Statistical analyses were performed using Wilcoxon signed-rank test where * 
indicates P<0.05, ** P<0.01, *** P<0.001. +ve=positive control. 
 
Figure 2. Western blot analyses of jejunal mHMGCS, and several fat-metabolism associated 
proteins pre-VLCD, post-VLCD/peri-RYGB and post-RYGB from the diet cohort of patients 
(n=12). The upper panels show Western blots of (A) mHMGCS, (B) CPT1A, (C) FATP4, (D) 
DGAT1 and (E) the ketone body-utilizing enzyme SCOT. In each panel representative protein 
bands from three of the patients for the protein of interest and the corresponding loading 
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control GAPDH are shown. Neighboring samples represent pre-VLCD (white bars above 
Western blots), post-VLCD/peri-RYGB (grey bars) and post-RYGB (black bars) samples 
from the same patient. In the lower panels expression of each protein of interest has been 
normalized to the loading control GAPDH and is presented in the bar graphs (ADU; arbitrary 
densitometric units). Statistical analyses were performed using Wilcoxon signed-rank test 
where * indicates P<0.05, ** P<0.01 and *** P<0.001. 
 
Figure 3. Western blot analyses of the effects of low-fat diet (LFD; white bars above blots) 
vs. high-fat diet (HFD; grey bars above blots) on mHMGCS protein expression. Upper panels 
show mHMGCS expression in (A) duodenum, (B) jejunum, (C) ileum, (D) jejunum vs. ileum 
and (E) liver in C57bl/6J mice on LFD or HFD. GAPDH was used as loading control and is 
shown below each corresponding mHMGCS band. Lower panels show the corresponding 
densitometric quantifications (ADU; arbitrary densitometric units) of mHMGCS vs. GAPDH.  
Note that (D) shows comparison of mHMGCS in the jejunum (light grey bar) vs. ileum (dark 
grey bar) in HFD fed mice to demonstrate the difference in expression levels between 
jejunum and ileum. (F) measurement of HB at 0, 15, 30 and 120 min in venous blood of 
mice fed LFD or HFD for 3 months. Prior to the experiment the mice were given an oral fat 
load (250 μl of Intralipid®) in order to supply substrate for ketogenesis. In some mice the oral 
fat load was mixed with HB, or the mHMGCS-inhibitor hymeglusin, as indicated. (G) shows 
the measurements from (F) at 120 min in a scatter plot (n=7-8). HB levels in venous blood 
were significantly higher in the HFD mice 120 min after oral gavage compared to LFD mice. 
Notably, the HB levels in HFD mice pretreated with the mHMGCS-inhibitor hymeglusin did 
not increase. (H) mice fed HFD for 3 weeks had significantly higher levels of ketone bodies 
in portal vein blood normalized to ketone bodies in peripheral blood, in contrast to mice fed 
LFD (n=9) after oral gavage with Intralipid® (500 μl). (I) absolute levels of ketone bodies 
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(mM) in peripheral and portal blood in the same mice as in panel H (n=9). Statistical analyses 
were performed using Mann-Whitney U-test where * indicates P<0.05 and ** P<0.01. 
 
Figure 4. (A) normalized GLP-1 levels in unstimulated (basal, 1mM glucose) mouse jejunal 
primary cultures (first cluster from the left), after stimulation with 10 mM glucose/0.1 mM 
IBMX (IG; second from left), or a combination of 10 mM glucose/0.1 mM IBMX and 10 mM 
HB (third from left), or a combination of 10 mM glucose/0.1 mM IBMX and 0.1 M 
somatostatin (fourth from left). (B) same group setup as A, but all groups were also treated 
with 500 ng/mL PTX in order to block Gi signaling. The different symbols depict replicates 
of jejunal primary cultures. Statistical analyses were performed using two-way ANOVA 
followed by Tukey’s HSD-test where * indicates P<0.05, ** P<0.01 and *** P<0.001. 
 
Figure 5. Schematic illustration of the proposed ketone body mechanism on GLP-1 
producing enteroendocrine cells (EECs). Chronic FFA exposure induces increased mHMGCS 
expression and HB production in jejunal epithelial cells in the villi tips. HB reaches the 
EECs via the venous microcirculation of the villi, and acts via FFAR3/GPR41 to inhibit the 
production/release of GLP-1. RYGB surgery may interfere with this mechanism by 
decreasing FFA availability and mHMGCS expression.  
 
Supplementary Figure 1.  
(A) the sampling sites of the jejunal mucosa peri- and postoperatively after RYGB (left and 
right panels, respectively).  
(B) example of 2D-gel electrophoresis obtained perioperatively (left panel) and 
postoperatively (right panel) from one individual. Examples of spots with changed intensities 
are encircled by white rectangles and highlighted in the lower panels by the green circles and 
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numbered according to software identification numbers. Mass spectrometry identification of 
these proteins is shown in Supplementary Table 2. Spots 1660, 1670 & 1678 represent 














Manufacturer Catalog number Application 
mHMGCS Santa Cruz Bio. sc-33828 Western blot and 
immunofluorescence 
CPT1A Abcam ab128568 Western blot 
FATP4 Atlas Antibodies HPA007293 Western blot 
DGAT1 Santa Cruz Bio. sc-271934 Western blot 
SCOT Santa Cruz Bio. sc-133988 Western blot 
GAPDH Imgenex IMG-5143A Western blot 
GAPDH Novus Biologicals NB100-56875 Western blot 
Secondary 
antibody 
Manufacturer Catalog number Application 
Goat anti-rabbit 
IgG-AP 
Santa Cruz Bio. sc-2007 Western blot 
Anti-mouse IgG 
HRP-linked 
Cell Signaling 7076 Western blot 
Anti-rabbit IgG 
HRP-linked 
Cell Signaling 7074 Western blot 
Alexa Fluor 488 
goat anti-rabbit 
ThermoFisher Sci. A11008 Immunofluorescence 
 
Supplementary Table 2. Paired analysis of 2D-gels peri- and 6 to 8 months postoperatively 
and identification of corresponding proteins with tandem mass spectrometry. 














Paired            
t-test 
 
 2838 8 Q01995 TAGLN Transgelin 611 -2.4 <0.001  
 2754 7 P30626 SRI Sorcin 301 -1.6 0.018  
 2093 6 P09493 TPM1 Tropomyosin alpha-1 chain 852 -1.6 0.013  
 2050 6 P09493 TPM1 Tropomyosin alpha-1 chain 1338 -1.6 0.010  
 1988 6 P07951 TPM2 Tropomyosin beta chain 1121 -1.6 0.024  
 1678 5 P54868 mHMGCS 
Hydroxymethylglutaryl-CoA   
synthase, mitochondrial 
558 -3.6 <0.001  
 1670 5 P41240 mHMGCS 
Hydroxymethylglutaryl-CoA   
synthase, mitochondrial 
577 -3.6 <0.001  
 1661 5 P41240 mHMGCS 
Hydroxymethylglutaryl-CoA   
synthase, mitochondrial 
530 -2.2 <0.001  
 1660 5 P54868 mHMGCS 
Hydroxymethylglutaryl-CoA   
synthase, mitochondrial 
652 -4.0 <0.001  
 1646 4 P05783 KRT18 Keratin, type I cytoskeletal 18 673 -2.2 <0.001  
 1640 4 P05783 KRT18 Keratin, type 1 cytoskeletal 18 1029 +1.9 0.008  
 1627 4 P35900 KRT20 Keratin, type I cytoskeletal 20 1852 +2.0 0.004  
 1606 4 P35900 KRT20 Keratin, type I cytoskeletal 20 1539 +1.7 0.011  
 1605 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1226 +2.0 0.033  
 1603 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1166 +1.8 0.027  
 1594 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1324 +1.9 0.032  
 1459 4 P05787 KRT8 Keratin, type II cytoskeletal 8 2026 +1.9 0.002  
 1441 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1872 +2.1 0.003  
 1432 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1942 +1.7 0.038  
 1427 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1567 +2.2 0.004  
 1421 4 P05787 KRT8 Keratin, type II cytoskeletal 8 1675 +2.0 0.015  
 935 3 P08238 HSP90AB1 Heat shock protein HSP 90-β 450 -1.6 0.006  
 478 1 P12109 COL6A1 Collagen alpha-1(VI) chain 701 -1.7 0.002  
 469 1 P12109 COL6A1 Collagen alpha-1(VI) chain 797 -1.9 0.004  
 431 2 P18206 VCL Vinculin 884 -1.7 0.021  
 420 2 P18206 VCL Vinculin 1100 -1.8 0.010  
 416 2 P18206 VCL Vinculin 1018 -1.7 0.018  
          
 
a) Accession number in Uniprot database 
b) Protein match score in Mascot search results 
 
 
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Supplementary Figure 1
